Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Application drying time for oxybutynin chloride topical gel.

Newman DK, Olsen SM, Dahl NV.

Urol Nurs. 2012 Sep-Oct;32(5):265-9.

PMID:
23472531
2.

Oxybutynin topical and transdermal formulations: an update.

Staskin DR, Salvatore S.

Drugs Today (Barc). 2010 Jun;46(6):417-25. doi: 10.1358/dot.2010.46.6.1487750. Review.

PMID:
20571610
3.

Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.

Staskin DR, Robinson D.

Expert Opin Pharmacother. 2009 Dec;10(18):3103-11. doi: 10.1517/14656560903451682. Review.

PMID:
19954278
4.

Transdermal drug delivery treatment for overactive bladder.

Dmochowski RR, Starkman JS, Davila GW.

Int Braz J Urol. 2006 Sep-Oct;32(5):513-20. Review.

5.

Oxybutynin gel for the treatment of overactive bladder.

Gomelsky A, Dmochowski RR.

Expert Opin Pharmacother. 2012 Jun;13(9):1337-43. doi: 10.1517/14656566.2012.688953. Review.

PMID:
22607010
6.

Topical oxybutynin (Gelnique) for overactive bladder.

[No authors listed]

Med Lett Drugs Ther. 2010 Feb 8;52(1331):10-1. Review. No abstract available.

PMID:
20216524
7.

Evolution of transdermal oxybutynin in the treatment of overactive bladder.

Sahai A, Mallina R, Dowson C, Larner T, Khan MS.

Int J Clin Pract. 2008 Jan;62(1):167-70. doi: 10.1111/j.1742-1241.2007.01623.x. Review.

PMID:
18173821
8.

Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.

Bolge SC, McDonnell DD, Chen A, Wan GJ.

Curr Med Res Opin. 2007 Aug;23(8):1903-12. Review.

PMID:
17610806
9.

Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.

Chapple CR, Rosenberg MT, Brenes FJ.

BJU Int. 2009 Oct;104(7):960-7. doi: 10.1111/j.1464-410X.2009.08545.x. Epub 2009 Apr 17. Review.

10.

[Intravesical treatment of overactive bladder syndrome].

Haferkamp A, Hohenfellner M.

Urologe A. 2006 Oct;45(10):1283-8. Review. German.

PMID:
16972089
11.

Transdermal oxybutynin: a new treatment for overactive bladder.

Davila GW.

Expert Opin Pharmacother. 2003 Dec;4(12):2315-24. Review.

PMID:
14640930
12.

Transdermal oxybutynin.

Baldwin CM, Keating GM.

Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008. Review.

PMID:
19275276
13.

Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.

Abramov Y, Sand PK.

Expert Opin Pharmacother. 2004 Nov;5(11):2351-9. Review.

PMID:
15500382
14.

Oxybutynin in detrusor overactivity.

Diokno A, Ingber M.

Urol Clin North Am. 2006 Nov;33(4):439-45, vii. Review.

PMID:
17011379
15.

Transdermal oxybutynin: sticking to the facts.

Cartwright R, Cardozo L.

Eur Urol. 2007 Apr;51(4):907-14; discussion 914. Epub 2006 Nov 27. Review.

PMID:
17157979
16.

Transdermal oxybutynin: a review.

Shaw GL, Patel HR.

Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):435-9. Review.

PMID:
17539749
17.

Intravesical oxybutynin in the pediatric neurogenic bladder.

Lazarus J.

Nat Rev Urol. 2009 Dec;6(12):671-4. doi: 10.1038/nrurol.2009.214. Epub 2009 Nov 10. Review.

PMID:
19901914
Items per page

Supplemental Content

Write to the Help Desk